Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017

Publisher Name :
Date: 13-Jun-2017
No. of pages: 42
Inquire Before Buying

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline landscape.

Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence. Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. Treatment includes topical (vaginal) estrogen and systemic estrogen therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 2 respectively.

Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).

- The pipeline guide reviews pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vaginal Atrophy (Atrophic Vaginitis) - Overview
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development
Allergan Plc
Foamix Pharmaceuticals Ltd
Mithra Pharmaceuticals SA
PEPTONIC medical AB
Sermonix Pharmaceuticals LLC
TherapeuticsMD Inc
Vaginal Atrophy (Atrophic Vaginitis) - Drug Profiles
(estradiol + progesterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estetrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
estradiol hemihydrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lasofoxifene tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxytocin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WC-3011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects
Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones
Featured News & Press Releases
Mar 01, 2017: Acerus Files a New Drug Submission for GYNOFLOR in Canada
May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor
Mar 24, 2016: Peptonic Medical receives approval for its clinical Phase 2b study
Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting
Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting
Jul 17, 2015: Last subject exits Peptonic Medical's phase 2b VVA study
Mar 23, 2015: Peptonic Medical's formulation patent to be approved in the USA
Mar 18, 2015: Patient recruitment to Peptonic Medical's phase 2b study soon completed
Feb 06, 2015: Peptonic Medical and Swetox enter collaboration on oxytocin
Dec 01, 2014: Peptonic Medical's formulation patent to be approved in Europe
Oct 28, 2014: First patients included in Peptonic Medical AB's clinical phase 2b study
Sep 08, 2014: PEPTONIC Medical gets approvals to start the next clinical study
Jul 04, 2014: PEPTONIC Medical Progress Towards Next Clinical Study
Mar 01, 2013: Peptonic Medical Receives New Formulation Patent For Vagitocin In Sweden
Jan 05, 2012: Peptonic's Oxytocin Receives Approval For Dose-Finding Trial From Swedish Medical Products Agency
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Allergan Plc, H1 2017
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Mithra Pharmaceuticals SA, H1 2017
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by PEPTONIC medical AB, H1 2017
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Sermonix Pharmaceuticals LLC, H1 2017
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD Inc, H1 2017
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Global and China Drugs for Vulvovaginal Candidiasis Market Research by Company, Type & Application 2013-2025
    Published: 15-Jun-2018        Price: US 2000 Onwards        Pages: 81
    Summary Market Segment as follows: By Type - Miconazole - Clotrimazole - Fluconazole - Econazole - Other By Application - Hospital & Clinic - Pharmacy By Company - Bayer - Perrigo - J & J - Pfizer - Bristol-Myers Squibb - Effik - Teva - Sanofi - Cisen Pharmaceutical - Kingyork Group The main contents of the repo......
  • Global Assisted Reproductive Technology Market Size, Status and Forecast 2025
    Published: 01-Jun-2018        Price: US 3300 Onwards        Pages: 95
    This report studies the global Assisted Reproductive Technology market, analyzes and researches the Assisted Reproductive Technology development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Merck KGaA - CooperSurgical, Inc. - Vitrolife AB. - Hamilton Thorne, Inc. - Nikon Corporation - Nidacon International AB - Laboratoire CCD - Planer PLC......
  • Global Oral Contraceptive Market Professional Survey Report 2018
    Published: 28-May-2018        Price: US 3500 Onwards        Pages: 103
    This report studies the global Oral Contraceptive market status and forecast, categorizes the global Oral Contraceptive market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Oral Contraceptive market is valued at xx million US$ in 2017 and is expected to reach xx million ......
  • Dysmenorrhea Global Clinical Trials Review, H1, 2018
    Published: 18-May-2018        Price: US 2500 Onwards        Pages: 195
    Dysmenorrhea Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Dysmenorrhea Global Clinical Trials Review, H1, 2018" provides an overview of Dysmenorrhea clinical trials scenario. This report provides top line data relating to the clinical trials on Dysmenorrhea. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by......
  • Male Hypogonadism Global Clinical Trials Review, H1, 2018
    Published: 18-May-2018        Price: US 2500 Onwards        Pages: 228
    Male Hypogonadism Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Male Hypogonadism Global Clinical Trials Review, H1, 2018" provides an overview of Male Hypogonadism clinical trials scenario. This report provides top line data relating to the clinical trials on Male Hypogonadism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of diseas......
  • Secondary (Hypogonadotropic) Hypogonadism Global Clinical Trials Review, H1, 2018
    Published: 18-May-2018        Price: US 2500 Onwards        Pages: 96
    Secondary (Hypogonadotropic) Hypogonadism Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Secondary (Hypogonadotropic) Hypogonadism Global Clinical Trials Review, H1, 2018" provides an overview of Secondary (Hypogonadotropic) Hypogonadism clinical trials scenario. This report provides top line data relating to the clinical trials on Secondary (Hypogonadotropic) Hypogonadism. Report includes an overview of trial numbers and their aver......
  • Peyronies Disease Global Clinical Trials Review, H1, 2018
    Published: 18-May-2018        Price: US 2500 Onwards        Pages: 44
    Peyronies Disease Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Peyronies Disease Global Clinical Trials Review, H1, 2018" provides an overview of Peyronies Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Peyronies Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of diseas......
  • North America Drugs for Vulvovaginal Candidiasis Market by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 18-May-2018        Price: US 4480 Onwards        Pages: 101
    The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after ......
  • Global and United States Postmenopausal Vaginal Atrophy Treatment Market Research by Company, Type & Application 2013-2025
    Published: 15-May-2018        Price: US 2000 Onwards        Pages: 91
    Summary Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase. Market Segment as follows: By Type - Creams - Ta......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs